Abstract
Various mechanisms have been implicated in the development of resistance of cancer cells to chemotherapy. Multidrug resistance (MDR) is a phenomenon in which cancer cells are resistant to the cytotoxic effects of various structurally and mechanistically unrelated chemotherapeutic agents. One major mechanism by which this occurs is through the over-expression of ATP-dependent drug efflux transporters such as the P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP). Regulation of MDR can occur at many levels including transcriptional, mRNA, protein and post-translational. In recent years it has been demonstrated that alterations in the expression and activity of the MDR transporters are seen in numerous tissues during an inflammatory response. An acute inflammatory response is associated with many conditions including infection, injury, hypoxia and stress and is known to result in the induction of several pro-inflammatory cytokines. Whether the function of cytokines can be harnessed in overcoming drug resistance of tumors has yet to be examined and explored. In this review, we will focus on the various studies investigating the regulation of MDR during an inflammatory response, in particular by cytokines. The mediators and pathways involved as well as the possible mechanisms of MDR regulation will be discussed. It is hoped that by understanding the clinical importance of inflammatory mediators in MDR, new doors will open and future insights will lead to the development of novel immunotherapeutics for the treatment of cancer.
Keywords: MDR, acute phase proteins, acute phase response, ABC transporters, cytokines, inflammation, multidrug resistance-associated protein, P-glycoprotein
Current Cancer Drug Targets
Title: Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Volume: 6 Issue: 4
Author(s): Emmanuel A. Ho and Micheline Piquette-Miller
Affiliation:
Keywords: MDR, acute phase proteins, acute phase response, ABC transporters, cytokines, inflammation, multidrug resistance-associated protein, P-glycoprotein
Abstract: Various mechanisms have been implicated in the development of resistance of cancer cells to chemotherapy. Multidrug resistance (MDR) is a phenomenon in which cancer cells are resistant to the cytotoxic effects of various structurally and mechanistically unrelated chemotherapeutic agents. One major mechanism by which this occurs is through the over-expression of ATP-dependent drug efflux transporters such as the P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP). Regulation of MDR can occur at many levels including transcriptional, mRNA, protein and post-translational. In recent years it has been demonstrated that alterations in the expression and activity of the MDR transporters are seen in numerous tissues during an inflammatory response. An acute inflammatory response is associated with many conditions including infection, injury, hypoxia and stress and is known to result in the induction of several pro-inflammatory cytokines. Whether the function of cytokines can be harnessed in overcoming drug resistance of tumors has yet to be examined and explored. In this review, we will focus on the various studies investigating the regulation of MDR during an inflammatory response, in particular by cytokines. The mediators and pathways involved as well as the possible mechanisms of MDR regulation will be discussed. It is hoped that by understanding the clinical importance of inflammatory mediators in MDR, new doors will open and future insights will lead to the development of novel immunotherapeutics for the treatment of cancer.
Export Options
About this article
Cite this article as:
Ho A. Emmanuel and Piquette-Miller Micheline, Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines, Current Cancer Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/156800906777441753
DOI https://dx.doi.org/10.2174/156800906777441753 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Latest Advances in Breast Sonography
Recent Patents on Medical Imaging What Characterizes Endothelial Dysfunction in Preeclampsia? -The Action of NO and the Production of Prostacyclin is Reduced, While EDHF is Preserved in Omental Resistance Arteries in Preeclamptic Women
Current Women`s Health Reviews Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Technological Barriers in the Use of Electrochemical Microsensors and Microbiosensors for in vivo Analysis of Neurological Relevant Substances
Current Neuropharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design The Coronary Collateral Circulation in Man
Current Cardiology Reviews Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Myocardial Perfusion and Coronary Vasomotor Function: Emerging Role of PET Imaging
Vascular Disease Prevention (Discontinued) Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Comparative Study of Eudragit RS 100 and RL 100 Nanoparticles as Ophthalmic Vehicle for Fungal Infection
Pharmaceutical Nanotechnology Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism